Center for Rare Neurological Diseases, Massachusetts General Hospital, Boston, MA, USA.
Harvard Medical School, Boston, MA, USA.
Orphanet J Rare Dis. 2022 Oct 4;17(1):370. doi: 10.1186/s13023-022-02518-z.
Metachromatic leukodystrophy (MLD), a relentlessly progressive and ultimately fatal condition, is a rare autosomal recessive lysosomal storage disorder caused by a deficiency of the enzyme arylsulfatase A (ARSA). Historically management has been palliative or supportive care. Hematopoietic stem cell transplantation is poorly effective in early-onset MLD and benefit in late-onset MLD remains controversial. Hematopoietic stem cell gene therapy, Libmeldy (atidarsagene autotemcel), was recently approved by the European Medicines Agency for early-onset MLD. Treatment benefit is mainly observed at an early disease stage, indicating the need for early diagnosis and intervention. This study contributes insights into the caregiver language used to describe initial MLD symptomatology, and thereby aims to improve communication between clinicians and families impacted by this condition and promote a faster path to diagnosis.
Data was collected through a moderator-assisted online 60-min survey and 30-min semi-structured follow-up telephone interview with 31 MLD caregivers in the United States (n = 10), France (n = 10), the United Kingdom (n = 5), and Germany (n = 6). All respondents were primary caregivers of a person with late infantile (n = 20), juvenile (n = 11) or borderline late infantile/juvenile (n = 1) MLD (one caregiver reported for 2 children leading to a sample of 32 individuals with MLD). Caregivers were asked questions related to their child's initial signs and symptoms, time to diagnosis and interactions with healthcare providers. These results highlight the caregiver language used to describe the most common initial symptoms of MLD and provide added context to help elevate the index of suspicion of disease. Distinctions between caregiver descriptions of late infantile and juvenile MLD in symptom onset and disease course were also identified.
This study captures the caregiver description of the physical, behavioral, and cognitive signs of MLD prior to diagnosis. The understanding of the caregiver language at symptom onset sheds light on a critical window of often missed opportunity for earlier diagnosis and therapeutic intervention in MLD.
异染性脑白质营养不良(MLD)是一种进行性、致命性疾病,属于罕见的常染色体隐性溶酶体贮积症,由芳基硫酸酯酶 A(ARSA)缺乏引起。过去,其治疗方法主要为姑息性或支持性治疗。造血干细胞移植对早发型 MLD 效果不佳,而晚发型 MLD 的获益仍存在争议。造血干细胞基因治疗药物 Libmeldy(atidarsagene autotemcel)最近被欧洲药品管理局批准用于治疗早发型 MLD。治疗效果主要在疾病早期观察到,这表明需要早期诊断和干预。本研究深入了解了照顾者用于描述 MLD 初始症状的语言,旨在改善受这种疾病影响的临床医生和家庭之间的沟通,并促进更快的诊断途径。
通过美国(n=10)、法国(n=10)、英国(n=5)和德国(n=6)的 31 名 MLD 照顾者的主持人协助的在线 60 分钟调查和 30 分钟半结构化随访电话访谈收集了数据。所有受访者均为晚发性婴儿型(n=20)、少年型(n=11)或边缘晚发性婴儿/少年型(n=1)MLD 患者的主要照顾者(一名照顾者报告了两名儿童,因此共有 32 名 MLD 患者)。照顾者被问及与孩子的初始体征和症状、诊断时间以及与医疗保健提供者的互动相关的问题。这些结果强调了照顾者用于描述 MLD 最常见初始症状的语言,并提供了更多的背景信息,有助于提高对疾病的怀疑指数。此外,还确定了晚发性婴儿型和少年型 MLD 症状发作和疾病过程中照顾者描述之间的区别。
本研究记录了照顾者在诊断前对 MLD 身体、行为和认知体征的描述。对症状发作时照顾者语言的理解,揭示了在 MLD 中错失早期诊断和治疗干预的关键机会窗口。